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The	 manifestations	 of	 human	 monocytic	 ehrlichiosis	
range	from	a	mild	febrile	syndrome	to	a	severe	multisystem	
illness.	Myocardial	involvement	is	uncommon.	We	report	a	
woman,	78	years	of	age,	who	was	treated	with	trimethoprim/
sulfamethoxazole	after	a	tick	bite,	in	whom	myocarditis	was	
subsequently	 diagnosed.	 She	 recovered	 completely	 after	
doxycycline	therapy.
Human monocytic ehrlichiosis (HME) is caused by an obligate intracellular gram-negative bacteria of the 
family Anaplasmataceae. The first reported case of eh-
rlichiosis occurred in a man, 51 years of age, in Arkansas, 
United States. The man experienced a prolonged febrile ill-
ness after being bitten by ticks. Four years later, Ehrlichia 
chaffeensis, the causative agent of this syndrome, was rec-
ognized (1). Ticks acquire E. chaffeensis from a reservoir 
host, the white-tailed deer, and transmit the organism to 
humans during blood meals (2).
The clinical manifestations of HME range from a mild 
febrile syndrome to severe multisystemic illness. Although 
ehrlichiosis has sometimes been referred to as Rocky 
mountain spotted fever without the rash, a rash is not un-
common (2). Gastrointestinal, pulmonary, and central 
nervous system symptoms are well described, but cardio-
vascular disease is rare (2). Including the patient described 
herein, 4 persons in whom HME was diagnosed have had 
myocardial involvement.
The Study
A woman, 78 years of age, who had a 4-day history of 
fevers, chills, fatigue, and myalgias sought medical treat-
ment after a syncopal episode. She denied dyspnea or chest 
pain. Ten days earlier, while in southern Virginia, she had 
noticed a tick on her ankle. After tick removal, the area be-
came inflamed, and the patient received trimethoprim/sulfa-
methoxazole (TMP/SMX) from a local urgent care center.
Her vital signs were as follows: oral temperature 
39.3°C, blood pressure 120/60 mm Hg, heart rate 90 
bpm, respiratory rate 16 breaths per min, and oxygen 
saturation 98% on room air. Except for a 2–cm erythem-
atous patch on the medial aspect of her right ankle, re-
sults of her physical examination were normal. Her leu-
kocyte count was 1.4 ×103 cells/μL (34% non-segmented 
neutrophils) and platelet count was 66 × 103/μL. Blood 
cultures were negative. The serum aspartate aminotrans-
ferase level was 173 U/L (reference <50 U/L), and the 
serum alanine aminotransferase level was 109 U/L (ref-
erence <50 U/L). Urinary sediment was unremarkable 
and a chest radiograph was normal. 
The following day, the patient became dyspneic. A 
room air arterial blood gas revealed a pH of 7.43 (ref-
erence range 7.38–7.42), PO
2
 of 70 mm Hg (reference 
range 75–100 mm Hg), and PCO
2
 of 20 mm Hg (refer-
ence range 38-42 mm Hg). Pulmonary congestion with-
out focal infiltrates was evident on a chest radiograph; an 
electrocardiogram indicated normal voltage, and saddle-
shaped S-T elevations in 6 leads did not indicate ischemic 
distribution. On hospital day 3, her cardiac enzyme levels 
were markedly elevated: creatine kinase was 2,524 U/L 
(reference <325 U/L), creatine kinase-MB 27.3 ng/mL 
(reference <2.3 ng/mL), and troponin 27.3 ng/mL (ref-
erence 0–0.03 ng/mLl). A transthoracic echocardiogram 
revealed left ventricular systolic dysfunction with global 
hypokinesis and an ejection fraction of 30% (reference 
range 55–70%). Cardiac magnetic resonance imaging 
showed mild atherosclerosis.
Review of the patient’s peripheral blood smear from 
the day of admission showed several monocytes with 
characteristic morulae. She was empirically treated with 
doxycycline, and experienced prompt defervescence. Her 
cardiac decompensation resolved over several days and an 
ejection fraction of 70% was noted on echocardiogram 10 
weeks after her admission.
Serologic results for  Borrelia bergdorferi, Rickettsia 
rickettsii, Anaplasma phagocytophilum, and Francisella 
tularensis were negative. Initial serologic analysis for E. 
chaffeensis demonstrated a positive result (IgM titer 320) 
and a negative IgG result . Convalescent-phase serologic 
analysis 1 month after discharge showed an IgG titer for E. 
chaffeensis of 8,192, indicating recent infection; markers of 
cardiac injury had returned to reference levels.
Conclusions
The Dallas criteria for a diagnosis of myocarditis are 
applied based on histopathologic findings of an inflamma-
tory cellular infiltrate with or without myocyte necrosis. 
Unfortunately, these criteria have low sensitivity, lack 
prognostic value, and necessitate an invasive procedure. 
Autopsy studies have shown that myocardial inflammation 
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is not homogeneous and that sampling issues can contrib-
ute to a high rate of false negative endomyocardial biop-
sies. In clinical practice, the diagnosis is made based on 
the clinical syndrome, cardiac biomarkers, and electrocar-
diographic and echocardiographic findings (3).
Although a wide variety of pathogenic organisms have 
been associated with myocarditis, the etiology of this dis-
order in most patients remains idiopathic. In those cases 
in which an etiologic agent has been identified, viruses, in 
particular coxsackie B viruses, have been most frequently 
implicated (4). Endomyocardial biopsies during the late 
1990s revealed other viral agents such as adenovirus, influ-
enza A and B, cytomegalovirus, parvovirus B-19, and Ep-
stein-Barr virus, among others (3,4). Myocardial involve-
ment and cardiac dysfunction are frequently recognized in 
patients with HIV infection.
Trichinella spiralis and Toxoplasma gondii have also 
been recognized as causes of myocarditis, and, outside the 
United States, trypanosomes are commonly recognized eti-
ologic agents (4). Bacteria can cause myocarditis through 
the effects of toxins, as is the case with diphtheria. Endo-
toxins have a direct suppressant effect on myocardial con-
tractility, and myocardial dysfunction can occur in patients 
infected with gram-negative bacteremia. Alternatively, the 
presence of other organismsa, such as Mycoplasma pneu-
moniae, Chlamydophilia spp., or Borrelia bergdorferi 
within the myocardium has been demonstrated, indicating 
a more direct effect (3,4).
Myocardial involvement is a rare complication 
of HME. Studies in which dog models were used have 
shown that acute infection with E. canis is a risk factor 
for myocardial injury (5). In 2 earlier reported cases of 
HME with myocardial involvement, previously healthy 
men had clinical symptoms of HME confirmed by se-
rologic analysis  and left ventricular dysfunction and 
electrocardiographic abnormalities developed, similar to 
those of the patient in this study. Myocarditis resolved 
in both patients after doxycycline therapy (6,7). A third 
case of HME-related myocarditis occurred in a patient 
with Wegener granulomatosis (8). The patient was im-
munosuppressed by use of a tumor necrosis factor-α in-
hibitor, which may have contributed to the more severe 
manifestation of HME. This patient also appeared to 
recover after initiation of doxycyline. Jahangir et al. re-
ported the sudden death of an otherwise healthy outdoor 
worker 19 days after the worker was bitten by a tick. An 
autopsy revealed transmural myocarditis and pulmonary 
congestion and serology consistent with human granulo-
cytic anaplasmosis (9).
There is a demonstrated association between use of tri-
methoprim/sulfamethoxazole and fulminant manifestations 
of rickettsial diseases; the mechanism is unknown. Severe 
cases of HME have been reported in otherwise healthy 
adolescents taking short courses of trimethoprim/sulfa-
methoxazole (10,11), and in transplant patients receiving 
long-term regimens of sulfa drugs as prophylaxis (12,13). 
Our patient’s disease severity may have been exacerbated 
by her recently prescribed regimen of trimethoprim/sulfa-
methoxazole.
Myocarditis associated with human monocytic eh-
rlichiosis is distinctly uncommon. The possibility that this 
condition is caused by simultaneous infection with another 
microorganism cannot be excluded, although such dual in-
fection is rare (14). Whether subclinical myocarditis may 
occur more frequently is unknown, but increased evalua-
tion of cardiac function may reveal that this is a more com-
mon phenomenon.
The mechanism whereby this organism produces tran-
sient myocardial dysfunction is unknown. Rickettsial in-
fection is characterized by direct endothelial cell infection 
and inflammation mediated by cytokine and chemokine ac-
tivity, which leads to increased microvascular permeability 
(15). Occasionally, small vessel occlusion and local isch-
emia may occur. In patients with ehrlichiosis, perivascular 
lymphohistiocytic infiltrates may be seen on histopatho-
logic examination (16). 
The observed improvement in myocardial function 
following doxycycline therapy in the patient in this study 
and in those previously described suggests that myocardial 
dysfunction may be caused by direct infection of the myo-
cyte or a toxic effect of sulfa drugs, or may be secondary to 
an innate inflammatory response mediated by E. chaffeen-
sis. It would be less likely to be a result of the host’s adap-
tive immune response, e.g., rheumatic fever. Considering 
the spread of this organism throughout the south central 
and southeastern United States, and the frequent use of tri-
methoprim/sulfamethoxazole to treat localized soft-tissue 
infections, it is necessary to recognize this pathogen as a 
treatable cause of myocarditis.
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